Skip to main content

Table 2 LAST Study Measurement of Patient-Reported Outcomes

From: Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Measure

# Items

PROMIS Fatiguea

CAT

PROMIS Depressiona

CAT

PROMIS Sleep Disturbancea

CAT

PROMIS GI Symptoms - Diarrheaa

2

PROMIS GI Symptoms - Nausea

1

PROMIS Physical Function

CAT

PROMIS Anxiety

CAT

PROMIS Sleep Related Impairment

CAT

PROMIS Pain Interference

CAT

PROMIS Pain Intensity

1

PROMIS Ability to Participate in Social Roles and Activities

CAT

PROMIS Social Isolation

CAT

PROMIS Applied Cognition General

CAT

PROMIS Interest in Sexual Activity

1

PROMIS Satisfaction with Sex Life

1

PROMIS Alcohol Use

2

PROMIS Global Self-Rated Health

1

PROMIS Global Quality of Life

1

EORTC CML Symptom Burden (includes 1 item on musculoskeletal paina)

13

Ability to work

2

Ability to pay monthly bills

1

Changes in use of pharmaceuticals

6

  1. Abbreviations: EORTC European Organisation for Research and Treatment of Cancer; CAT Computerized Adaptive Test; GI Gastrointestinal; PROMIS Patient-Reported Outcomes Measurement Information System
  2. aHypothesized change of ≥0.3 standardized effect size